OCC Insider Trading

Insider Ownership Percentage: 24.50%
Insider Buying (Last 12 Months): A$21,270.00
Insider Selling (Last 12 Months): A$0.00

Orthocell Insider Trading History Chart

This chart shows the insider buying and selling history at Orthocell by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Orthocell Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for OCC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Orthocell Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/24/2024John WielenInsiderBuy20,000A$0.38A$7,620.00
4/15/2024John WielenInsiderBuy35,000A$0.39A$13,650.00
1/17/2024Kim Beazley ACInsiderIssued2,000,000A$0.41A$820,000.00
11/20/2023Fiona WoodInsiderIssued2,000,000A$0.41A$820,000.00
11/15/2023John WielenInsiderIssued250,000A$0.37A$91,250.00
11/7/2023Paul AndersonInsiderIssued500,000A$0.39A$192,500.00
6/13/2023Paul AndersonInsiderBuy9,907A$0.36A$3,516.99
6/9/2023Paul AndersonInsiderBuy31,343A$0.36A$11,252.14
11/7/2022Lars LidgrenInsiderBuy45,000A$0.43A$19,350.00
9/23/2021Paul AndersonInsiderSell435,273A$0.48A$208,495.77
See Full Table

SEC Filings (Institutional Ownership Changes) for Orthocell (ASX:OCC)

2.49% of Orthocell stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Orthocell logo
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Read More on Orthocell

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

669,530 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11

Who are the company insiders with the largest holdings of Orthocell?

Orthocell's top insider investors include:
  1. Fiona Wood (Insider)
  2. John Wielen (Insider)
  3. Kim Beazley AC (Insider)
  4. Lars Lidgren (Insider)
  5. Paul Anderson (Insider)
Learn More about top insider investors at Orthocell.